EUVIMEDEUVIMED entdecken
Open Access

Prediction of response to lomustine-based chemotherapy in glioma patients at recurrence using MRI and FET PET

Michael M Wollring, Jan-Michael Werner, Elena K Bauer, Caroline Tscherpel, Garry S Ceccon, Philipp Lohmann iD, Gabriele Stoffels iD, Christoph Kabbasch, Roland Goldbrunner, Gereon R Fink, Karl-Josef Langen, Norbert Galldiks iD

Neuro-Oncology · 04.05.2023 · 25 (5) · 984-994

DOI: 10.1093/neuonc/noac229 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Neuro-Oncology, online erschienen am 10.10.2022. Verfasst von Michael M Wollring und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany. Hauptthemen laut MEDLINE: Brain Neoplasms, Glioma. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Deutsche Forschungsgemeinschaft.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

We evaluated O-(2-[18F]fluoroethyl)-l-tyrosine (FET) PET and MRI for early response assessment in recurrent glioma patients treated with lomustine-based chemotherapy.

Methods

Thirty-six adult patients with WHO CNS grade 3 or 4 gliomas (glioblastoma, 69%) at recurrence (median number of recurrences, 1; range, 1–3) were retrospectively identified. Besides MRI, serial FET PET scans were performed at baseline and early after chemotherapy initiation (not later than two cycles). Tumor-to-brain ratios (TBR), metabolic tumor volumes (MTV), the occurrence of new distant hotspots with a mean TBR >1.6 at follow-up, and the dynamic parameter time-to-peak were derived from all FET PET scans. PET parameter thresholds were defined using ROC analyses to predict PFS of ≥6 months and OS of ≥12 months. MRI response assessment was based on RANO criteria. The predictive values of FET PET parameters and RANO criteria were subsequently evaluated using univariate and multivariate survival estimates.

Results

After treatment initiation, the median follow-up time was 11 months (range, 3–71 months). Relative changes of TBR, MTV, and RANO criteria predicted a significantly longer PFS (all P ≤ .002) and OS (all P ≤ .045). At follow-up, the occurrence of new distant hotspots (n ≥ 1) predicted a worse outcome, with significantly shorter PFS (P = .005) and OS (P < .001). Time-to-peak changes did not predict a significantly longer survival. Multivariate survival analyses revealed that new distant hotspots at follow-up FET PET were most potent in predicting non-response (P < .001; HR, 8.578).

Conclusions

Data suggest that FET PET provides complementary information to RANO criteria for response evaluation of lomustine-based chemotherapy early after treatment initiation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Brain NeoplasmsGliomaAdultHumansLomustineRetrospective StudiesRadiopharmaceuticalsMagnetic Resonance ImagingPositron-Emission TomographyTyrosine

Stichwörter der Autor:innen

CCNUamino acid PETglioblastomanitrosourea

Substanzen

LomustineRadiopharmaceuticalsTyrosine

Autor:innen und Institutionen

  • Department of Neurology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
  • Institute of Neuroscience and Medicine (INM-3, -4), Research Center Juelich, Juelich, Germany.
  • Department of Stereotaxy and Functional Neurosurgery, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
  • Institute of Radiology, Division of Neuroradiology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
  • Department of General Neurosurgery, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
  • Center of Integrated Oncology (CIO), Universities of Aachen, Bonn, Cologne, and Duesseldorf, Germany.

ORCID-Profile: Philipp Lohmann, Gabriele Stoffels, Norbert Galldiks

Förderung

  • Deutsche Forschungsgemeinschaft

Zitieren

APA

Wollring, M. M., Werner, J. M., Bauer, E. K., Tscherpel, C., Ceccon, G. S., Lohmann, P., Stoffels, G., Kabbasch, C., Goldbrunner, R., Fink, G. R., Langen, K. J., & Galldiks, N. (2023). Prediction of response to lomustine-based chemotherapy in glioma patients at recurrence using MRI and FET PET. Neuro-Oncology, 25(5), 984-994. https://doi.org/10.1093/neuonc/noac229

Vancouver

Wollring MM, Werner JM, Bauer EK, Tscherpel C, Ceccon GS, Lohmann P, et al. Prediction of response to lomustine-based chemotherapy in glioma patients at recurrence using MRI and FET PET. Neuro-Oncology. 2023;25(5):984-994. doi:10.1093/neuonc/noac229

BibTeX
@article{Wollring2023,
  author = {Wollring, Michael M and Werner, Jan-Michael and Bauer, Elena K and Tscherpel, Caroline and Ceccon, Garry S and Lohmann, Philipp and Stoffels, Gabriele and Kabbasch, Christoph and Goldbrunner, Roland and Fink, Gereon R and Langen, Karl-Josef and Galldiks, Norbert},
  title = {Prediction of response to lomustine-based chemotherapy in glioma patients at recurrence using MRI and FET PET},
  journal = {Neuro-Oncology},
  year = {2023},
  volume = {25},
  number = {5},
  pages = {984--994},
  doi = {10.1093/neuonc/noac229}
}
Kostenlos starten →